Chad Glasser is the Senior Director of Clinical Research at Tisento Therapeutics, a company focused entirely on developing treatments for mitochondrial disease. In this episode of Energy in Action, Chad speaks with host Marcy Young about the origins of Tisento, the science behind their lead compound Zagociguat, and why the company’s name—meaning “I hear you” in Italian—reflects their commitment to listening to patients.
They dive into the current PRIZM clinical trial for individuals with MELAS syndrome, including what makes this study unique: home visits, oral medication, and a crossover design that ensures all participants receive the active drug. Chad explains how the team shaped the trial based on patient interviews, and what’s next for the drug development process. For anyone living with mitochondrial disease—or considering participation in clinical research—this conversation offers clarity, hope, and a glimpse into the future of rare disease treatment.
Resources and Ways to Connect
Learn more about the PRIZM Trial:
Visit TisentoTX.com
Search for the PRIZM study on ClinicalTrials.gov
Stay Connected with MitoAction:
Meet Jessica Fein!
ENERGY IN ACTION - EPISODE 053 Finding Help with the Cost of Medications Carla Dellaporta is the Director of User Engagement for NeedyMeds, a...
PARENTS AS RARE - EPISODE 052 Lisa Weinberger - Be Your Own Advocate, Listen To Your Body, Take Control of Your Health, & Ask...